Amgen acquires sales rights to Roche's Neupogen and Neulasta in 100 markets

US-based biotechnology firm Amgen (AMGN) has acquired sales rights to Swiss drugmaker Roche's two drugs Neupogen (filgrastim) and Neulasta (pegfilgrastim), which are used to boost the immune systems of cancer patients on chemotherapy in more than 100…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news